EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape

Iseult M Browne iD, Monica Esteban Garcia, Alicia F C Okines

Oncology Research · 2026

DOI: 10.32604/or.2026.082829 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Iseult M Browne und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) is defined by the absence of oestrogen receptor, progesterone receptor, and HER2 expression, and carries a disproportionate burden of breast cancer-related mortality due to its aggressive biology and historically limited therapeutic options. The treatment landscape of metastatic TNBC has undergone a fundamental transformation over the past decade, driven by immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and the identification of actionable genomic alterations. This review provides a comprehensive, clinically oriented appraisal of the current and emerging therapeutic landscape of metastatic TNBC, encompassing its molecular underpinnings and tumour microenvironment biology. We critically evaluate the evolving roles of immune checkpoint inhibition, ADCs, PARP inhibitors, and novel targeted approaches, discuss mechanisms of resistance and biomarker limitations, and propose a framework for rational, biomarker-guided treatment selection and sequencing to support evidence-based clinical decision-making in this rapidly evolving field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHumansFemaleBiomarkers, TumorImmune Checkpoint InhibitorsMolecular Targeted TherapyNeoplasm MetastasisPoly(ADP-ribose) Polymerase InhibitorsTumor MicroenvironmentImmunoconjugates

Stichwörter der Autor:innen

BRCA mutationPARP inhibitorsTriple negative breast cancerantibody-drug conjugatesbiomarkersimmune checkpoint inhibitionpembrolizumabsacituzumab govitecantreatment sequencing

Substanzen

Biomarkers, TumorImmune Checkpoint InhibitorsPoly(ADP-ribose) Polymerase InhibitorsImmunoconjugates

Autor:innen und Institutionen

  • The Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.

ORCID-Profile: Iseult M Browne

Zitieren

APA

Browne, I. M., Esteban Garcia, M., & Okines, A. F. C. (2026). Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape. Oncology Research. https://doi.org/10.32604/or.2026.082829

Vancouver

Browne IM, Esteban Garcia M, Okines AFC. Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape. Oncology Research. 2026. doi:10.32604/or.2026.082829

BibTeX
@article{Browne2026,
  author = {Browne, Iseult M and Esteban Garcia, Monica and Okines, Alicia F C},
  title = {Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape},
  journal = {Oncology Research},
  year = {2026},
  doi = {10.32604/or.2026.082829}
}
Kostenlos starten →